UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000011011 |
|---|---|
| Receipt number | R000012885 |
| Scientific Title | Effect of warfarin use on bleeding complications: bronchoscopy with transbronchial biopsies for peripheral lesion |
| Date of disclosure of the study information | 2013/06/20 |
| Last modified on | 2018/08/30 14:56:32 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of warfarin use on bleeding complications: bronchoscopy with transbronchial biopsies
for peripheral lesion
Acronym
Effect of warfarin use on bleeding complications: bronchoscopy with transbronchial biopsies
for peripheral lesion
Scientific Title
Effect of warfarin use on bleeding complications: bronchoscopy with transbronchial biopsies
for peripheral lesion
Scientific Title:Acronym
Effect of warfarin use on bleeding complications: bronchoscopy with transbronchial biopsies
for peripheral lesion
Region
| Japan |
Condition
Condition
Subjects of bronchoscopy during warfarin therapy
Classification by specialty
| Pneumology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Consider the following items in order to implement safer bronchoscopy.
1. measuring amount of bleeding during bronchoscopy
2. comparing frequency of bleeding and thromboembolism after bronchoscopy
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1. amount of bleeding during bronchoscopy
2. complications
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
Interventions; during warfarin therapy
Interventions/Control_2
Control; not use antithrombogenic drug
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. subjects of a bronchoscopy
2. cases written informed consent was obtained
3. cases of suspected to malignant disease for peripheral lesion
4. satisfy following items
Plate >= 50,000/mm3
ALT <= 150 IU/L
AST <= 150 IU/L
T.Bil <= 1.5 mg/dL
Cr <= 1.5 mg/dL
1.5<INR<3.0
Key exclusion criteria
1.medical history of bleeding tendency or hemoptysis
2.concurrent use of steroid therapy
3.cases of needing high invasive procedure (cauterization or stent)
4.cases of emergency examination
5.patients with active concomitant pregnancy
6.patients with serious drug allergic reactions.
7.patients who were deemed inappropriate to the subject of this study by attending physician
Target sample size
120
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | takamasa hotta |
Organization
Shimane University Faculty of Medicine
Division name
Department of Biochemistry
Zip code
Address
89-1 Enya-cho Izumo Shimane 693-8501 JAPAN
TEL
0853-23-2111
hotta.takamasa@gmail.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | takamasa hotta |
Organization
Shimane University Faculty of Medicine
Division name
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine
Zip code
Address
89-1 Enya-cho Izumo Shimane 693-8501 JAPAN
TEL
0853-23-2111
Homepage URL
hotta.takamasa@gmail.com
Sponsor or person
Institute
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
Institute
Department
Personal name
Funding Source
Organization
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 06 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2013 | Year | 04 | Month | 22 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2018 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2018 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2018 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2018 | Year | 07 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2013 | Year | 06 | Month | 20 | Day |
Last modified on
| 2018 | Year | 08 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012885
